Literature DB >> 7477055

Comparison of sister chromatid exchange frequency in peripheral lymphocytes in lung cancer cases and controls.

T J Cheng1, D C Christiani, J K Wiencke, J C Wain, X Xu, K T Kelsey.   

Abstract

Cytogenetic alterations have been associated with the occurrence of many cancers. However, limited data exist to address whether increased chromosomal changes in surrogate normal tissue are similarly associated with malignancy. As part of an ongoing case-control study of lung cancer, we have studied the factors that affect sister chromatid exchange (SCE) frequency in lymphocytes from lung cancer patients. Further, we sought to investigate whether the factors that affect SCE frequencies were comparable in lung cancer cases and controls. Cases had newly diagnosed, operable primary lung cancer. Controls were friends and spouses of cases. Detailed information on smoking, family history of cancer, medical history, and environmental and occupational exposures was obtained in an interviewer-administered questionnaire. Intake of antioxidants was also determined through the administration of a validated semiquantitative food frequency questionnaire. Metabolic traits studied included the polymorphic glutathione-S-transferase class mu (GST-mu) and variants of P450 isoenzymes CYP1A1 and CYP 2D6. Overall, 78 cases and 78 controls were included in the analysis. Although there was a small number of lung cancer patients who had never smoked in the study (9% of cases), these patients had higher SCE frequencies than current or former smokers. This suggests that factors associated with genomic instability may also play a role in the pathogenesis of lung cancer. The best fit model for SCE frequency, which had been previously generated from control data alone, included age, gender, smoking, GST-mu, and vitamin A intake. However, when this model was applied to lung cancer patients, smoking was not associated with an elevated SCE frequency. Thus, it is not clear that SCE frequency data in prevalent lung cancer cases and controls are comparable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477055     DOI: 10.1016/0165-7992(95)00049-6

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

1.  A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire.

Authors:  Corina Lesseur; Diane Gilbert-Diamond; Angeline S Andrew; Rebecca M Ekstrom; Zhongze Li; Karl T Kelsey; Carmen J Marsit; Margaret R Karagas
Journal:  Toxicol Lett       Date:  2012-01-28       Impact factor: 4.372

2.  Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

Authors:  Bess Levin; Denise Lech; Bernard Friedenson
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

3.  Sister chromatid exchanges and micronuclei in peripheral lymphocytes of shoe factory workers exposed to solvents.

Authors:  Marià Pitarque; Alexander Vaglenov; Maria Nosko; Sonya Pavlova; Vera Petkova; Ari Hirvonen; Amadeu Creus; Hannu Norppa; Ricard Marcos
Journal:  Environ Health Perspect       Date:  2002-04       Impact factor: 9.031

4.  Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies.

Authors:  Zheng Ye; Honglin Song; Julian P T Higgins; Paul Pharoah; John Danesh
Journal:  PLoS Med       Date:  2006-03-07       Impact factor: 11.069

Review 5.  Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes.

Authors:  H Norppa
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

Review 6.  Effect of glutathione S-transferase M1 polymorphisms on biomarkers of exposure and effects.

Authors:  R J Srám
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

7.  Sister Chromatid Exchange and Genomic Instability in Soft Tissue Sarcomas: Potential Implications for Response to DNA-Damaging Treatments.

Authors:  Abdulazeez Salawu; Kristin Wright; Afnan Al-Kathiri; Lynda Wyld; Malcolm Reed; Karen Sisley
Journal:  Sarcoma       Date:  2018-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.